🔗 Share this article

While the United States undertakes unprecedented revisions to its vaccination guidelines, one figure has emerged in a surprising turn: Tracy Beth Høeg, a US-based sports physician and epidemiologist who first made her name by questioning COVID-19 vaccinations in the global health crisis and has focused upon potential deaths following Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Immunization Program

Public health authorities planned to reveal major changes to the childhood immunization program recently, aligning the US with the Danish immunization schedule, according to reports – a significant shift that would place the US out of alignment with much of the global community with no evidence for improved outcomes. The planned update has been postponed until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is set to speak at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the division this calendar year.

A Shift at the Agency

Høeg's temporary position might represent a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a increased emphasis upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for ending specific childhood shot schedules in the US to become more similar to Denmark's approach, a country with universal health coverage and a citizenry about the population of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccines – traditionally the purview of Dr. Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has no apparent background in pharmaceutical research, regulation or management, which has been typical for former heads of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“She appears not to have the necessary background” for running the CDER, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in leading a major agency. She lacks background in drug approvals.”

Previous directors of CBER would “grasp legal statutes and the science of medication creation”, noted Dr. Janet Woodcock. “Frankly, she lacks the type of experience that prior appointees who led CBER have had.”

CDER has an enormous range of responsibilities at the agency, she stated.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office approves numerous generic drugs. There’s a biologic copycat branch, over-the-counter program and other areas, and all of those must be supervised,” she noted. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a substantial administrative element to the job, which supervises in excess of 5,000 staff members. “It is a huge leadership role, if you do it right,” Woodcock concluded.

Agency Reaction and Disputed Policies

Regarding inquiries about Dr. Høeg's credentials and whether this selection indicates increased cooperation among agency officials on vaccines, a spokesperson responded that the “questions are based on inaccurate presumptions”.

“Her experience aligns with the functions of her position,” the official stated, citing the months Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the commissioner’s controversial expedited review system, a contentious one-day therapy clearance system that allegedly troubled her predecessors. “How are these therapies being chosen for this voucher program? Who takes the choices?” Howard asked. “There’s a lot of secrecy occurring at the agency right now.”

Broadly speaking, he said, “the agency looks to be trending towards less stringent regulations of all drugs, aside from immunizations.”

Public History on Immunizations

Regarding immunizations, Høeg has a more established, if troubling, history, some experts observe. She authored a study using unconfirmed public submissions to determine the rate of heart inflammation following COVID-19 immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to imply Covid vaccinations are pose a greater threat than they are.

Among her “policy goals” for the current federal leadership featured changing guidelines for recently developed shots and discontinuing “optional” immunizations, she stated post-election on a audio program. At the agency, Høeg has allegedly floated the idea of preventing adolescent males from receiving COVID-19 vaccines.

“She is an thorough dogmatist who starts off with her preconceived notions and works backwards to fit the data in a highly deceptive, fraudulent fashion,” Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of fellow dissenters, {like|